Zydus Therapeutics Inc.
Clinical trials sponsored by Zydus Therapeutics Inc., explained in plain language.
US subsidiary of Zydus Lifesciences, developing pharmaceutical products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Liver drug study seeks to understand how body processes medication in scarred livers Results expected Dec 2026 (estimated)
- New drug study aims to understand how liver disease affects medication Results expected Dec 2026 (estimated)
- Hope for liver disease: new drug trial targets PBC symptoms Results expected Apr 2027 (estimated)
-
New drug hope for fatty liver in PCOS women?
Disease control Stopped earlyThis study tested a drug called saroglitazar in women with polycystic ovary syndrome (PCOS) who also have nonalcoholic fatty liver disease (NAFLD). The goal was to see if the drug could safely reduce liver fat over 24 weeks compared to a placebo. The trial was planned for 60 wome…
Phase 2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Fatty liver drug trial in HIV patients stalls after enrolling just 4 people
Disease control Stopped earlyThis study tested a drug called saroglitazar magnesium for nonalcoholic fatty liver disease (NAFLD) in people with HIV. The trial aimed to see if the drug could reduce liver fat over 24 weeks. However, the study was terminated early and only enrolled 4 participants, so no meaning…
Phase 2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 26, 2026 12:33 UTC